Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mark Layton

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|June 8, 2012
Clinical problem-solving. The wolf at the doorBenjamin J Uttenthal, D Mark Layton, Timothy J Vyse, et al.
Blood|October 11, 2003
Protein 4.2 is critical to CD47-membrane skeleton attachment in human red cellsKris Noel Dahl, Ranganath Parthasarathy, Connie M Westhoff, et al.
Lancet (London, England)|January 24, 2007
Myocardial infarction in sickle-cell diseaseJirí Pavlů, Riaz E Ahmed, Declan P O'Regan, et al.
Human Molecular Genetics|April 18, 2013
Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutationValentina S Caputo, Joana R Costa, Kalliopi Makarona, et al.
The New England Journal of Medicine|April 20, 2007
Targeted therapy for inherited GPI deficiencyAntonio M Almeida, Yoshiko Murakami, Alastair Baker, et al.
Blood|October 9, 2014
Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiencyJoana R Costa, Valentina S Caputo, Kalliopi Makarona, et al.
Blood|August 15, 2002
Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man: an interaction between the Rh complex and the band 3 complexLesley J Bruce, Sandip Ghosh, May Jean King, et al.
Lancet (London, England)|August 14, 2022
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 studyKevin H M Kuo, D Mark Layton, Ashutosh Lal, et al.
British Journal of Haematology|May 21, 2025
Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 studyKevin H M Kuo, D Mark Layton, Ashutosh Lal, et al.
Blood Cells, Molecules & Diseases|May 10, 2003
Combined glucose-6-phosphate dehydrogenase and glucosephosphate isomerase deficiency can alter clinical outcomeJulia L Clarke, Tom J Vulliamy, David Roper, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|June 8, 2012
Clinical problem-solving. The wolf at the doorBenjamin J Uttenthal, D Mark Layton, Timothy J Vyse, et al.
Blood|October 11, 2003
Protein 4.2 is critical to CD47-membrane skeleton attachment in human red cellsKris Noel Dahl, Ranganath Parthasarathy, Connie M Westhoff, et al.
Lancet (London, England)|January 24, 2007
Myocardial infarction in sickle-cell diseaseJirí Pavlů, Riaz E Ahmed, Declan P O'Regan, et al.
Human Molecular Genetics|April 18, 2013
Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutationValentina S Caputo, Joana R Costa, Kalliopi Makarona, et al.
The New England Journal of Medicine|April 20, 2007
Targeted therapy for inherited GPI deficiencyAntonio M Almeida, Yoshiko Murakami, Alastair Baker, et al.
Blood|October 9, 2014
Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiencyJoana R Costa, Valentina S Caputo, Kalliopi Makarona, et al.
Blood|August 15, 2002
Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man: an interaction between the Rh complex and the band 3 complexLesley J Bruce, Sandip Ghosh, May Jean King, et al.
Lancet (London, England)|August 14, 2022
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 studyKevin H M Kuo, D Mark Layton, Ashutosh Lal, et al.
British Journal of Haematology|May 21, 2025
Long-term efficacy and safety of mitapivat in non-transfusion-dependent α- or β-thalassaemia: An open-label phase 2 studyKevin H M Kuo, D Mark Layton, Ashutosh Lal, et al.
Blood Cells, Molecules & Diseases|May 10, 2003
Combined glucose-6-phosphate dehydrogenase and glucosephosphate isomerase deficiency can alter clinical outcomeJulia L Clarke, Tom J Vulliamy, David Roper, et al.
Pageof 4